Arcus Biosciences is a high-risk speculation with major upcoming catalysts, despite stock declines and Gilead's exit from the ...

Gilead Sciences (GILD) ended the recent trading session at $111.88, demonstrating a +0.54% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of ...

With the FDA appearing to be undergoing major disruption under new leadership, BofA analyst Tim Anderson says one way to assess the risk from ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...

Protagonist (Nasdaq: PTGX) is one of a handful of Bay Area drug developers ready to ask the Food and Drug Administration to ...

The Wadesboro Police Department is mourning the loss of K-9 Blitz, who died during a traffic stop incident that escalated ...

Hulu announced that it is developing a series based on Margaret Atwood's 2019 novel "The Testaments," which is a follow-up to ...

Bruce Miller knew for a long time how he wanted to bring the story to a conclusion,' says EP Eric Tuchman. 'It's about June's ...

As the sixth and final season of The Handmaid’s Tale is nearing its premiere next week, production on its sequel series The ...

If you thought the final season of The Handmaid’s Tale would wrap the torment Gilead has put June Osborne -and you – through, think again. A sequel series The Testaments, set 15 years later, has now ...

Gilead to soon return as Hulu orders sequel to hit show The Handmaid’s Tale. The new show will be called The Testaments. Hulu ...